VEGFA and prostate carcinoma: C2Cnt has shown anti-angiogenic and anti-inflammatory properties in prostate cancer cells, downregulating vascular endothelial growth factor (VEGF) and the chemokine CXCR4/CXCL12 pathways, which are critical for tumor vascularization and metastasis [27].